Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]
Status PubMed-not-MEDLINE Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu tisková chyba
PubMed
34412950
DOI
10.1016/j.annonc.2021.07.011
PII: S0923-7534(21)02209-2
Knihovny.cz E-zdroje
- Publikační typ
- tisková chyba MeSH
British Columbia Cancer Agency Vancouver Canada
CHU Liege and Liège University Liège Belgium
David Geffen School of Medicine at UCLA Los Angeles USA
Highlands Oncology Group Fayetteville USA
Hospital Universitario Virgen Macarena Seville Spain
Istituto Nazionale Tumori IRCCS 'Fondazione G Pascale' Naples Italy
Masaryk Memorial Cancer Institute Brno Czech Republic
Multidisciplinary Breast Centre Universitair Ziekenhuis Leuven Leuven Belgium
Netherlands Cancer Institute Borstkanker Onderzoek Groep Study Center Amsterdam The Netherlands
Novartis Pharma AG Basel Switzerland
Novartis Pharmaceuticals Corporation East Hanover USA
Practice for Hematology and Internal Oncology Velbert Germany
Citace poskytuje Crossref.org